神经肿瘤学临床试验的考虑因素。
Clinical Trial Considerations in Neuro-oncology.
机构信息
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
出版信息
Curr Treat Options Oncol. 2021 Jul 2;22(9):78. doi: 10.1007/s11864-021-00875-8.
Abstract
Clinical trials play a critical role in discovering new treatments, but the path to regulatory approval can be cumbersome and time consuming. Efforts to increase the efficiency and interpretability of clinical trials within the neuro-oncology community have focused on standardization of response assessment, development of consensus guidelines for clinical trial conduct, decentralization of clinical trials, removal of barriers to clinical trial accrual, and re-examination of patient eligibility criteria.
摘要
临床试验在发现新疗法方面发挥着关键作用，但获得监管批准的过程可能繁琐且耗时。神经肿瘤学界为提高临床试验的效率和可解释性所做的努力集中在反应评估的标准化、临床试验实施共识指南的制定、临床试验去中心化、消除临床试验入组障碍以及重新审查患者资格标准上。
相似文献
1
Clinical Trial Considerations in Neuro-oncology.神经肿瘤学临床试验的考虑因素。
Curr Treat Options Oncol. 2021 Jul 2;22(9):78. doi: 10.1007/s11864-021-00875-8.
2
GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials.《神经肿瘤学指南：研究性研究标准——基于手术的治疗性临床试验报告》
J Neurooncol. 2007 Apr;82(2):211-20. doi: 10.1007/s11060-006-9271-5. Epub 2006 Dec 5.
3
Tele-neuro-oncology: Current Practices and Future Directions.远程神经肿瘤学：当前实践与未来方向。
Curr Oncol Rep. 2022 Jan;24(1):99-103. doi: 10.1007/s11912-021-01176-x. Epub 2022 Jan 20.
4
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.临床研究纳入标准的现代化：ASCO-癌症研究之友绩效状态工作组的建议。
Clin Cancer Res. 2021 May 1;27(9):2424-2429. doi: 10.1158/1078-0432.CCR-20-3868. Epub 2021 Feb 9.
5
[The design of clinical studies in neurooncology].[神经肿瘤学临床研究的设计]
Zh Vopr Neirokhir Im N N Burdenko. 2008 Jan-Mar(1):3-10.
6
The role of nonrandomized trials in the evaluation of oncology drugs.非随机临床试验在肿瘤药物评价中的作用。
Clin Pharmacol Ther. 2015 May;97(5):502-7. doi: 10.1002/cpt.86. Epub 2015 Apr 7.
7
Response assessment in neuro-oncology.神经肿瘤学中的反应评估。
Curr Oncol Rep. 2011 Feb;13(1):50-6. doi: 10.1007/s11912-010-0143-y.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.神经肿瘤学中的免疫治疗反应评估：RANO工作组报告
Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1.
10
Pathology is a necessary and informative tool in oncology clinical trials.病理学是肿瘤临床试验中必要且有价值的工具。
J Pathol. 2014 Jan;232(2):185-9. doi: 10.1002/path.4261.
引用本文的文献
1
Artificial intelligence tools for optimising recruitment and retention in clinical trials: a scoping review protocol.人工智能工具在临床试验中优化招募和保留的应用：系统评价方案。
BMJ Open. 2024 Mar 19;14(3):e080032. doi: 10.1136/bmjopen-2023-080032.
2
Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis.2000年至2022年眼科基因治疗的进展与展望：一项文献计量分析
Heliyon. 2023 Jul 14;9(7):e18228. doi: 10.1016/j.heliyon.2023.e18228. eCollection 2023 Jul.
3
Novel Clinical Trial Designs in Neuro-Oncology.神经肿瘤学中的新型临床试验设计。
Neurotherapeutics. 2022 Oct;19(6):1844-1854. doi: 10.1007/s13311-022-01284-x. Epub 2022 Aug 15.
本文引用的文献
1
Phase 0/microdosing approaches: time for mainstream application in drug development?零期/微剂量研究方法：是否到了在药物研发中主流应用的时机？
Nat Rev Drug Discov. 2020 Nov;19(11):801-818. doi: 10.1038/s41573-020-0080-x. Epub 2020 Sep 8.
2
The New Normal in Clinical Trials: Decentralized Studies.临床试验的新常态：去中心化研究。
Ann Neurol. 2020 Nov;88(5):863-866. doi: 10.1002/ana.25892. Epub 2020 Sep 11.
3
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.神经肿瘤学中的 0 期和机会窗临床试验设计：一项 RANO 综述。
Neuro Oncol. 2020 Nov 26;22(11):1568-1579. doi: 10.1093/neuonc/noaa149.
4
Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.弥漫性内在脑桥胶质瘤的反应评估：来自儿科神经肿瘤学反应评估（RAPNO）工作组的建议。
Lancet Oncol. 2020 Jun;21(6):e330-e336. doi: 10.1016/S1470-2045(20)30166-2.
5
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.儿童高级别胶质瘤的疗效评估：儿童神经肿瘤疗效评估（RAPNO）工作组的建议。
Lancet Oncol. 2020 Jun;21(6):e317-e329. doi: 10.1016/S1470-2045(20)30173-X.
6
Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.儿童低级别胶质瘤的反应评估：来自儿童神经肿瘤学反应评估（RAPNO）工作组的建议。
Lancet Oncol. 2020 Jun;21(6):e305-e316. doi: 10.1016/S1470-2045(20)30064-4.
7
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey.COVID-19 对肿瘤学临床试验开展的早期影响及长期变革机遇：美国临床肿瘤学会调查研究结果。
JCO Oncol Pract. 2020 Jul;16(7):417-421. doi: 10.1200/OP.20.00275. Epub 2020 May 12.
8
Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey.医疗服务提供者报告的将患者转诊至神经肿瘤学临床试验的挑战与障碍：来自神经肿瘤学会成员调查的报告
Neurooncol Pract. 2020 Jan;7(1):38-51. doi: 10.1093/nop/npz038. Epub 2019 Sep 10.
9
Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.脑转移瘤临床试验中标准化脑肿瘤成像方案的共识建议。
Neuro Oncol. 2020 Jun 9;22(6):757-772. doi: 10.1093/neuonc/noaa030.
10
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.胶质母细胞瘤患者报告结局评估在临床护理和研究中的应用：神经肿瘤学协作组的报告。
Lancet Oncol. 2020 Feb;21(2):e97-e103. doi: 10.1016/S1470-2045(19)30796-X.
Zotero 插件